Oculis reported improved visual function and maintained retinal structure in its Phase 2 study. These early results support Privosegtor's promise, but do not prove it will be approved or help a broad group of patients.
That gives Oculis more support for the idea that Privosegtor may protect nerve cells in the eye and brain. The study is still at an early stage, so these findings do not show the treatment will be approved or help a broad group of patients.
Follow Oculis (OCS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for OCS